Senti Biosciences Inc. announced the completion of enrollment in its Phase 1 clinical trial of SENTI-202, a CD33/FLT3-targeting Logic Gated CAR NK cell therapy for patients with relapsed or refractory acute myeloid leukemia (R/R AML). The company recently presented positive clinical data from this study at the American Society of Hematology $(ASH)$ Annual Meeting, demonstrating deep, MRD-negative, durable complete remissions and a favorable safety profile in a heavily pretreated patient population. SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may expedite its development and review process. Senti Biosciences plans to engage with the U.S. Food and Drug Administration in the first half of 2026 to discuss the potential pivotal registration program for SENTI-202 in R/R AML and possible expansion to newly diagnosed and pediatric AML indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652651-en) on February 11, 2026, and is solely responsible for the information contained therein.